)
Visual22 Oct 2025
Epiroc's cash spent on M&A
Innate Pharma (IPH) investor relations material
Innate Pharma Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary17 Sep, 2025
Executive summary
Strategic focus on advancing IPH4502, lacutamab, and monalizumab, with organizational streamlining and a planned 30% workforce reduction to prioritize resources.
€15m equity investment by Sanofi in April 2025, strengthening the partnership and capital base.
Corporate governance changes include a shift to a CEO/board structure, new board appointments, and establishment of an R&D Committee.
Emphasis on leveraging differentiated antibody engineering, innate immunity, and clinical data to advance transformative cancer therapies.
Chief Scientific Officer Eric Vivier transitioned to an advisory role, with Yannis Morel assuming CSO responsibilities.
Financial highlights
Cash, cash equivalents, and financial assets totaled €70.4m as of June 30, 2025, down from €91.1m at year-end 2024, supporting operations through Q3 2026.
Revenue and other income for H1 2025 was €4.9m, mainly from collaborations with AstraZeneca and Sanofi, and government research funding.
Operating expenses decreased to €30.3m (H1 2025), with R&D expenses at €20.5m (67.8% of total), down €8.6m year-over-year.
Net loss of €21.3m for H1 2025, compared to a net loss of €24.8m in H1 2024.
Net financial gain of €4.1m in H1 2025, mainly from favorable foreign exchange movements.
Outlook and guidance
Cash runway expected until end of Q3 2026, including impact of restructuring.
Key milestones: first patient data for IPH4502 in H1 2026, preliminary safety/activity data in H1 2026, and high-level readout of PACIFIC-9 Phase 3 trial with monalizumab in H2 2026.
Lacutamab Phase 3 protocol near completion; trial initiation targeted for 2026 pending financing or partnership, with potential accelerated approval in 2027.
Streamlining and organizational changes to be completed in H1 2026.
Lacutamab Phase III financing strategy
IPH4502 differentiation vs. other Nectin-4 ADCs
Future R&D allocation post strategic refocus
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Innate Pharma earnings date
Investor Update28 Oct, 2025
Next Innate Pharma earnings date
Investor Update28 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications. It generates its products from the expression platforms based on its phage display and dAb technologies. The company's lead product is NexoBrid, which is a treatment for severe burns that can be used outside of the European Union; and Phase 3 NExoBrid clinical trial is completed in Europe. Innate Pharma S.A. was founded in 2000 as Innate ImmunoPharmaceuticals S.A.; and it changed its name to Innate Pharma S.A. in 2011. Innate Pharma S.A. has operations in Saint Prex, Switzerland; and Sophia Antipolis, France. Innate Pharma S.A is based in Marseille, France.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage